4/23
03:53 am
lxrx
Lexicon Pharmaceuticals (LXRX) to Present Phase 2b Pilavapadin Data [Yahoo! Finance]
Medium
Report
Lexicon Pharmaceuticals (LXRX) to Present Phase 2b Pilavapadin Data [Yahoo! Finance]
4/17
08:00 am
lxrx
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
Low
Report
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
3/24
08:00 am
lxrx
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
Medium
Report
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
3/23
11:25 am
lxrx
Lexicon Pharmaceuticals (LXRX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
Lexicon Pharmaceuticals (LXRX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $6.00 price target on the stock.
3/23
07:40 am
lxrx
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 [Yahoo! Finance]
Medium
Report
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 [Yahoo! Finance]
3/23
07:30 am
lxrx
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
Medium
Report
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
3/20
06:20 pm
lxrx
H.C. Wainwright Remains a Buy on Lexicon Pharmaceuticals (LXRX) [Yahoo! Finance]
Medium
Report
H.C. Wainwright Remains a Buy on Lexicon Pharmaceuticals (LXRX) [Yahoo! Finance]
3/12
03:09 pm
lxrx
Lexicon Pharmaceuticals (LXRX) was given a new $6.00 price target by HC Wainwright.
Low
Report
Lexicon Pharmaceuticals (LXRX) was given a new $6.00 price target by HC Wainwright.
3/11
08:00 am
lxrx
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
Medium
Report
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
3/10
11:02 am
lxrx
Lexicon Pharmaceuticals (LXRX) had its price target raised by Citigroup Inc. from $2.10 to $2.30. They now have a "buy" rating on the stock.
Low
Report
Lexicon Pharmaceuticals (LXRX) had its price target raised by Citigroup Inc. from $2.10 to $2.30. They now have a "buy" rating on the stock.
3/5
12:51 pm
lxrx
Lexicon Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Neutral
Report
Lexicon Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
3/5
11:44 am
lxrx
Lexicon Pharmaceuticals (LXRX) had its price target raised by HC Wainwright from $4.00 to $6.00. They now have a "buy" rating on the stock.
Medium
Report
Lexicon Pharmaceuticals (LXRX) had its price target raised by HC Wainwright from $4.00 to $6.00. They now have a "buy" rating on the stock.
3/5
07:26 am
lxrx
Lexicon: Q4 Earnings Snapshot [Yahoo! Finance]
Medium
Report
Lexicon: Q4 Earnings Snapshot [Yahoo! Finance]
3/5
07:18 am
lxrx
Lexicon Pharmaceuticals GAAP EPS of -$0.04 beats by $0.03, revenue of $5.49M beats by $2.35M [Seeking Alpha]
Medium
Report
Lexicon Pharmaceuticals GAAP EPS of -$0.04 beats by $0.03, revenue of $5.49M beats by $2.35M [Seeking Alpha]
3/5
07:15 am
lxrx
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates [Yahoo! Finance]
Medium
Report
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates [Yahoo! Finance]
3/5
06:59 am
lxrx
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
Low
Report
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
3/3
04:34 pm
lxrx
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences [Yahoo! Finance]
Low
Report
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences [Yahoo! Finance]
3/3
04:01 pm
lxrx
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences
Low
Report
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences
2/26
08:30 am
lxrx
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
Low
Report
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
2/23
01:21 am
lxrx
How The Lexicon Pharmaceuticals (LXRX) Story Is Shifting With Fine Tuned Targets And Trials [Yahoo! Finance]
Low
Report
How The Lexicon Pharmaceuticals (LXRX) Story Is Shifting With Fine Tuned Targets And Trials [Yahoo! Finance]
2/6
05:17 pm
lxrx
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
Medium
Report
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
1/30
02:50 am
lxrx
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
High
Report
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
1/29
04:31 pm
lxrx
Lexicon Announces Proposed Public Offering of Common Stock
High
Report
Lexicon Announces Proposed Public Offering of Common Stock
1/27
08:33 am
lxrx
How A Reset Price Target Is Reframing The Story For Lexicon Pharmaceuticals (LXRX) [Yahoo! Finance]
Medium
Report
How A Reset Price Target Is Reframing The Story For Lexicon Pharmaceuticals (LXRX) [Yahoo! Finance]
1/23
08:43 am
lxrx
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary [Yahoo! Finance]
Medium
Report
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary [Yahoo! Finance]